Drug Profile
Research programme: antibody-drug conjugate therapeutics - Celltrion
Alternative Names: CT P26Latest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator Celltrion
- Class Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; Immunomodulators; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 01 Sep 2023 Discontinued - Preclinical for Breast cancer in South Korea (unspecified route)
- 28 Apr 2018 No recent reports of development identified for preclinical development in Breast-cancer in South Korea
- 01 Mar 2014 Preclinical trials in Breast cancer in South Korea (unspecified route) before March 2014